Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Discontinued Operations: 2019-2021

Historic Cash from Discontinued Operations for Agios Pharmaceuticals (AGIO) over the last 3 years, with Dec 2021 value amounting to -$93.2 million.

  • Agios Pharmaceuticals' Cash from Discontinued Operations fell 335.48% to -$4.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$93.2 million, marking a year-over-year decrease of 99.15%. This contributed to the annual value of -$93.2 million for FY2021, which is 99.15% down from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Cash from Discontinued Operations of -$93.2 million as of FY2021, which was down 99.15% from -$46.8 million recorded in FY2020.
  • In the past 5 years, Agios Pharmaceuticals' Cash from Discontinued Operations registered a high of -$46.8 million during FY2020, and its lowest value of -$134.5 million during FY2019.
  • Moreover, its 3-year median value for Cash from Discontinued Operations was -$93.2 million (2021), whereas its average is -$91.5 million.
  • Per our database at Business Quant, Agios Pharmaceuticals' Cash from Discontinued Operations skyrocketed by 65.18% in 2020 and then plummeted by 99.15% in 2021.
  • Agios Pharmaceuticals' Cash from Discontinued Operations (Yearly) stood at -$134.5 million in 2019, then surged by 65.18% to -$46.8 million in 2020, then slumped by 99.15% to -$93.2 million in 2021.